Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas

Journal of Laboratory Automation

Volumn 20, Issue 4, 2015, Pages 423-437

  Ding, Xianting ^a,b,c,d   Mohd Abdul Rashid, Masturah Bte ^a,b   Toh, Tan Boon ^a   Silva, Aleidy ^c   Nurrul Abdullah, Lissa ^a   Ho, Chih Ming ^c   Ho, Dean ^d   Chow, Edward Kai Hua ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Department of Civil and Environmental Engineering   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2 NBDG; combination therapy; feedback system control; glucose; GLUT1; high content screening; phenotypic personalized medicine

Indexed keywords

CELL DEATH; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; FEEDBACK; FLUORESCENCE; METABOLISM;

2-NBDG; COMBINATION THERAPY; FEEDBACK SYSTEMS; GLUT1; HIGH-CONTENT SCREENING;

GLUCOSE;

2 [N (7 NITROBENZ 2 OXA 1,3 DIAZOL 4 YL)AMINO] 2 DEOXYGLUCOSE; FLUORESCENT DYE; GLUCOSE TRANSPORTER; HEXOKINASE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 2-(N-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)AMINO)-2-DEOXYGLUCOSE; 4 CHLORO 7 NITROBENZOFURAZAN; DEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 1; SLC2A1 PROTEIN, HUMAN;

ANALYTICAL PARAMETERS; ARTICLE; CALCEIN-AM ASSAY; CELL DEATH; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG TARGETING; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEPATOCELLULAR CARCINOMA CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; LIVER CELL CARCINOMA; MRNA EXPRESSION ASSAY; PROLIFERATIVE INDEX; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; LIVER TUMOR; METABOLISM; PERSONALIZED MEDICINE; TUMOR CELL LINE;

4-CHLORO-7-NITROBENZOFURAZAN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYGLUCOSE; FLUORESCENT DYES; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LIVER NEOPLASMS; PRECISION MEDICINE;

EID: 84938874414     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068215579612     Document Type: Article

References (38)

1. D.M.ParkinF.BrayJ.FerlayP.Pisani, Global Cancer Statistics, 2002. CA Cancer J. Clin. 2005, 55, 74–108.
2. J.M.LlovetA.BurroughsJ.BruixHepatocellular Carcinoma. Lancet2003, 362, 1907–1917.
3. S.M.WilhelmC.CarterL.Tang. Bay 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the Raf/Mek/Erk Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004, 64, 7099–7109.
4. Y.S.ChangJ.AdnaneP.A.Trail. Sorafenib (Bay 43-9006) Inhibits Tumor Growth and Vascularization and Induces Tumor Apoptosis and Hypoxia in Rcc Xenograft Models. Cancer Chemother. Pharmacol. 2007, 59, 561–574.
5. A.VillanuevaJ.M.LlovetSecond-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. Clin Cancer Res. 2012, 18, 1824–1826.
6. G.K.Abou-AlfaD.AmadoriA.Santoro. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (Hcc) and Child-Pugh a versus B Cirrhosis. Gastrointest. Cancer Res. 2011, 4, 40–44.
7. O.WarburgOn the Origin of Cancer Cells. Science1956, 123, 309–314.
8. R.J.DeBerardinisJ.J.LumG.Hatzivassiliou. The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cell Metab. 2008, 7, 11–20.
9. T.AmannU.MaegdefrauA.Hartmann. Glut1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis. Am. J. Pathol. 2009, 174, 1544–1552.
10. M.L.MachedaS.RogersJ.D.BestMolecular and Cellular Regulation of Glucose Transporter (Glut) Proteins in Cancer. J. Cell Physiol. 2005, 202, 654–662.
11. M.YounesR.W.BrownM.Stephenson. Overexpression of Glut1 and Glut3 in Stage I Nonsmall Cell Lung Carcinoma Is Associated with Poor Survival. Cancer1997, 80, 1046–1051.
12. T.KawamuraT.KusakabeT.Sugino. Expression of Glucose Transporter-1 in Human Gastric Carcinoma: Association with Tumor Aggressiveness, Metastasis, and Patient Survival. Cancer2001, 92, 634–641.
13. R.S.HaberA.RathanK.R.Weiser. Glut1 Glucose Transporter Expression in Colorectal Carcinoma: A Marker for Poor Prognosis. Cancer1998, 83, 34–40.
14. T.KalirB.Y.WangM.Goldfischer. Immuno-histochemical Staining of Glut1 in Benign, Borderline, and Malignant Ovarian Epithelia. Cancer2002, 94, 1078–1082.
15. S.Ganapathy-KanniappanM.ValiR.Kunjithapatham. 3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy. Curr. Pharm. Biotechnol. 2010, 11, 510–517.
16. I.Al-ShyoukhF.YuJ.Feng. Systematic Quantitative Characterization of Cellular Responses Induced by Multiple Signals. BMC Syst. Biol. 2011, 5, 88.
17. X.DingD.J.SanchezA.Shahangian. Cascade Search for Hsv-1 Combinatorial Drugs with High Antiviral Efficacy and Low Toxicity. Int. J. Nanomed. 2012, 7, 2281.
18. H.WangD.-K.LeeK.-Y.Chen. Mechanism-Independent Optimization of Combinatorial Nanodiamond and Unmodified Drug Delivery Using a Phenotypically-Driven Platform Technology. ACS Nano. 2015. doi:10.1021/acsnano.5b00638.
19. X.DingH.XuC.Hopper. Use of Fractional Factorial Designs in Antiviral Drug Studies. Qual. Rel. Eng. Int. 2013, 29, 299–304.
20. J.JaynesX.DingH.Xu. Application of Fractional Factorial Designs to Study Drug Combinations. Stat. Med. 2013, 32, 307–318.
21. R.RudalskaD.DauchT.Longerich. In Vivo Rnai Screening Identifies a Mechanism of Sorafenib Resistance in Liver Cancer. Nat. Med. 2014, 20, 1138–1146.
22. R.ChenD.ZhuX.Ye. Establishment of Three Human Liver Carcinoma Cell Lines and Some of Their Biological Characteristics In Vitro. Sci. Sin. 1980, 23, 236–247.
23. K.YoshiokaK.B.OhM.Saito. Evaluation of 2-[N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-Yl)Amino]-2-Deoxy-D-Glucose, a New Fluorescent Derivative of Glucose, for Viability Assessment of YeastCandida albicans. Appl. Microbiol. Biotechnol. 1996, 46, 400–404.
24. K.YamadaM.SaitoH.Matsuoka. A Real-Time Method of Imaging Glucose Uptake in Single, Living Mammalian Cells. Nat. Protoc. 2007, 2, 753–762.
25. C.ZouY.WangZ.Shen2-Nbdg as a Fluorescent Indicator for Direct Glucose Uptake Measurement. J. Biochem. Biophys. Methods2005, 64, 207–215.
26. H.XuJ.JaynesX.DingCombining Two-Level and Three-Level Orthogonal Arrays for Factor Screening and Response Surface Exploration. Stat. Sin. 2014, 24, 269–289.
27. R.E.AirleyA.MobasheriHypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics. Chemotherapy2007, 53, 233–256.
28. R.A.MedinaG.I.OwenGlucose Transporters: Expression, Regulation and Cancer. Bio. Res. 2002, 35, 9–26.
29. L.GongZ.CuiP.Chen. Reduced Survival of Patients with Hepatocellular Carcinoma Expressing Hexokinase Ii. Med. Oncol. 2012, 29, 909–914.
30. R.G.O’NeilL.WuN.MullaniUptake of a Fluorescent Deoxyglucose Analog (2-Nbdg) in Tumor Cells. Mol. Imag. Biol. 2005, 7, 388–392.
31. B.DwarakanathV.JainTargeting Glucose Metabolism with 2-Deoxy-D-Glucose for Improving Cancer Therapy. Future Oncol. 2009, 5, 581–585.
32. G.MaschekN.SavarajW.Priebe. 2-Deoxy-D-Glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers in Vivo. Cancer Res. 2004, 64, 31–34.
33. A.MoisanY.-K.LeeJ.D.Zhang. White-to-Brown Metabolic Conversion of Human Adipocytes by Jak Inhibition. Nat. Cell. Bio. 2015, 17, 57–67.
34. B.H.KimM.KimC.H.Yin. Inhibition of the Signalling Kinase Jak3 Alleviates Inflammation in Monoarthritic Rats. Br. J. Pharm. 2011, 164, 106–118.
35. E.CavalcantiM.GiganteV.Mancini. Jak3/Stat5/6 Pathway Alterations Are Associated with Immune Deviation in CD8 T Cells in Renal Cell Carcinoma Patients. J Biomed. Biotechnol. 2010, 2010, 935764.
36. M.A.FriasC.MontessuitJak-Stat Signaling and Myocardial Glucose Metabolism. JAKSTAT2013, 2, e26458.
37. D.Langin, Adipose Tissue Lipolysis Revisited (Again!): Lactate Involvement in Insulin Antilipolytic Action. Cell Metab. 2010, 11, 242–243.
38. C.RanH.LiuY.Hitoshi. Proliferation-Independent Control of Tumor Glycolysis by Pdgfr-Mediated Akt Activation. Cancer Res. 2013, 73, 1831–1843.